Transgenic Soybean Production of Bioactive Human Epidermal Growth Factor (EGF)
Schmidt, Monica A.
Warner, Brad W.
Herman, Eliot M.
AffiliationSchool of Plant Sciences, University of Arizona
School of Animal & Comparative Biomedical Sciences, University of Arizona,
MetadataShow full item record
PublisherPublic Library of Science
CitationTransgenic Soybean Production of Bioactive Human Epidermal Growth Factor (EGF) 2016, 11 (6):e0157034 PLOS ONE
RightsCopyright: © 2016 He et al. This is an open access article distributed under the terms of the Creative Commons Attribution License.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractNecrotizing enterocolitis (NEC) is a devastating condition of premature infants that results from the gut microbiome invading immature intestinal tissues. This results in a life-threatening disease that is frequently treated with the surgical removal of diseased and dead tissues. Epidermal growth factor (EGF), typically found in bodily fluids, such as amniotic fluid, salvia and mother’s breast milk, is an intestinotrophic growth factor and may reduce the onset of NEC in premature infants. We have produced human EGF in soybean seeds to levels biologically relevant and demonstrated its comparable activity to commercially available EGF. Transgenic soybean seeds expressing a seed-specific codon optimized gene encoding of the human EGF protein with an added ER signal tag at the N’ terminal were produced. Seven independent lines were grown to homozygous and found to accumulate a range of 6.7 +/- 3.1 to 129.0 +/- 36.7 μg EGF/g of dry soybean seed. Proteomic and immunoblot analysis indicates that the inserted EGF is the same as the human EGF protein. Phosphorylation and immunohistochemical assays on the EGF receptor in HeLa cells indicate the EGF protein produced in soybean seed is bioactive and comparable to commercially available human EGF. This work demonstrates the feasibility of using soybean seeds as a biofactory to produce therapeutic agents in a soymilk delivery platform.
VersionFinal published version
SponsorsThis research was supported by NIH# R21 DK094065 (BWW, PI; EMH and MAS coPIs), University Research Strategic Alliance Program; Washington University in St. Louis, and the Children’s Surgical Sciences Research Institute – St. Louis Children’s Hospital Foundation.
- Soybean-derived recombinant human epidermal growth factor protects against experimental necrotizing enterocolitis.
- Authors: Isani M, Illingworth L, Herman E, Schmidt M, Barron L, Bowling J, Elizee M, Bai I, Gayer C, Grishin A, Erwin CR, Ford HR, Warner BW
- Issue date: 2018 Jun
- Expression of functional recombinant human growth hormone in transgenic soybean seeds.
- Authors: Cunha NB, Murad AM, Cipriano TM, Araújo AC, Aragão FJ, Leite A, Vianna GR, McPhee TR, Souza GH, Waters MJ, Rech EL
- Issue date: 2011 Aug
- A Comparison of transgenic and wild type soybean seeds: analysis of transcriptome profiles using RNA-Seq.
- Authors: Lambirth KC, Whaley AM, Blakley IC, Schlueter JA, Bost KL, Loraine AE, Piller KJ
- Issue date: 2015 Oct 1
- Heparin-binding epidermal growth factor-like growth factor overexpression in transgenic mice increases resistance to necrotizing enterocolitis.
- Authors: Radulescu A, Zhang HY, Yu X, Olson JK, Darbyshire AK, Chen Y, Besner GE
- Issue date: 2010 Oct
- Epidermal growth factor reduces autophagy in intestinal epithelium and in the rat model of necrotizing enterocolitis.
- Authors: Maynard AA, Dvorak K, Khailova L, Dobrenen H, Arganbright KM, Halpern MD, Kurundkar AR, Maheshwari A, Dvorak B
- Issue date: 2010 Sep